STERIS Reports 9.2% Revenue Growth in Third Quarter of Fiscal 2026

STERIS plc reported a significant increase in financial performance for the third quarter and first nine months of fiscal 2026, with total revenues reaching $1,496.2 million for the three months ended December 31, 2025, a 9.2% increase from $1,370.6 million in the same period last year. For the nine months, revenues rose 9.3% to $4,347.5 million compared to $3,979.0 million in the prior year. The growth was attributed to higher volume and pricing across all three business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.

The company's gross profit margin for the third quarter was 43.8%, slightly down from 44.5% in the previous year, while the nine-month gross profit margin improved marginally to 44.4% from 44.3%. The decrease in the quarterly gross profit margin was primarily due to unfavorable impacts from tariffs and inflation, which outweighed benefits from pricing and productivity improvements. Operating income for the third quarter increased to $273.2 million from $245.3 million year-over-year, and for the nine months, it rose to $785.0 million from $650.5 million, reflecting the positive effects of increased sales volume and pricing.

In terms of strategic developments, STERIS completed two tuck-in acquisitions during the first nine months of fiscal 2026, totaling approximately $23.4 million, aimed at expanding its product and service offerings in the Healthcare segment. The company also continued to benefit from its restructuring plan initiated in May 2024, which has led to the elimination of approximately 300 positions and is expected to enhance profitability by approximately $25 million annually.

Operationally, STERIS reported a total cash flow from operations of $1,006.0 million for the first nine months of fiscal 2026, compared to $887.3 million in the prior year. Free cash flow also increased to $737.6 million from $588.1 million, driven by higher earnings and reduced capital expenditures. The company’s debt-to-total capital ratio improved to 21.1% as of December 31, 2025, down from 25.2% a year earlier, indicating a stronger balance sheet.

Looking ahead, STERIS remains optimistic about its growth trajectory, supported by ongoing demand for its healthcare products and services, particularly in light of an aging global population and increasing healthcare needs. The company anticipates that its strategic initiatives, including acquisitions and operational efficiencies, will continue to drive revenue growth and enhance profitability in the upcoming quarters.